BUZ INVESTORS Cannabinoid Joint Venture Lexaria Bioscience Corp (OTCQB:LXRP) (CSE:LXX) (the "Company") and Neutrisci International Inc ("Neutrisci") (TSX-V:NU, OTCQB:NRXCF, Frankfurt-1N9) have completed and signed the previously announced joint venture

Lexaria Bioscience Corp. (LXRP) Announces Exercised Warrants and Options

Lexaria Announces Exercised Warrants and Options

BUZ INVESTORS Cannabinoid Joint Venture Lexaria Bioscience Corp <span data-recalc-dims=(OTCQB:LXRP) (CSE:LXX) (the "Company") and Neutrisci International Inc ("Neutrisci") (TSX-V:NU, OTCQB:NRXCF, Frankfurt-1N9) have completed and signed the previously announced joint venture" width="300" height="225" srcset="https://i1.wp.com/investorsbuz.com/wp-content/uploads/2017/04/Lexaria-Corp-boost-1.jpg?resize=300%2C225&ssl=1 300w, https://i1.wp.com/investorsbuz.com/wp-content/uploads/2017/04/Lexaria-Corp-boost-1.jpg?w=480&ssl=1 480w" sizes="(max-width: 300px) 100vw, 300px" />

 Lexaria Bioscience Corp. (LXRP) (CSE:LXX) (the “Company” or “Lexaria”) announces it has received US$91,443.50 from the exercise of warrants and options previously granted. The stock warrants were exercised at the price of US$0.14 and the stock options were exercised at US$0.2273 for a total of 636,025 common shares being issued. All warrants and options are being exercised by third parties who are neither officers nor directors of the Company.
No commissions or placement fees have been paid related to the funds received from these warrant and option exercises. Proceeds will be used for general corporate purposes.



 

 Lexaria Bioscience Corp

Separately the Company has entered a consulting agreement with a third party that has resulted in the issuance of 500,000 warrants, each warrant good to buy one share at the price of US$0.44 and valid for exercise for one year.

The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.



 

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )



BUZ INVESTORS Cannabinoid Joint Venture Lexaria Bioscience Corp (OTCQB:LXRP) (CSE:LXX) (the "Company") and Neutrisci International Inc ("Neutrisci") (TSX-V:NU, OTCQB:NRXCF, Frankfurt-1N9) have completed and signed the previously announced joint venture

INVESTORS Lexaria Bioscience Corp. (LXRP) Engages NetworkNewsWire for Corporate Communications Solutions

Lexaria Bioscience Corp. Engages NetworkNewsWire for Corporate Communications Solutions

Lexaria Bioscience Corp. (“the Company”) ( OTCQB : LXRP ) ( CSE : LXX ), an innovative company licensing proprietary technology

PRESS RELEASE Lexaria Bioscience Corp. (“the Company”) ( OTCQB : LXRP ) ( CSE : LXX ), an innovative company licensing proprietary technology for delivery of bioactive compounds including cannabinoids, announces that it has engaged the corporate communications expertise of NetworkNewsWire (“NNW”).
“We are excited to be on the cutting-edge of bioscience, developing better ways to deliver health-enhancing cannabinoids to the body,” says Lexaria Bioscience CEO and chairman of the board Chris Bunka. “As we continue to fulfil our mission of improving our customers’ quality of life through our patented process, we expect our new association with NetworkNewsWire to enhance our initiatives to keep shareholders and potential investors aware of our progress and potential.”

NNW is a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. NNW’s strategies help public and private organizations find their voice and build market visibility. As part of the Client-Partner relationship with Lexaria Bioscience, NNW will leverage its investor-based distribution network of over 5,000 key syndication outlets, various newsletters, social media channels, blogs, and other outreach tools to generate greater brand awareness for the Company.



Lexaria Bioscience Corp

“Lexaria Bioscience is headed in an exciting direction with proprietary technology for improving taste and delivery of bioactive compounds, and is a first mover in the plant-to-bloodstream niche,” states Sherri Franklin, director of Content Marketing for NNW. “We look forward to working with Chris and the team at Lexaria to develop a communications strategy that best tells their story to the investment community.”

About Lexaria

Lexaria Bioscience Corp. is a biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company’s lipophilic enhancement technology has been proven to enhance the bioavailability of orally ingested cannabinoids, while also improving taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company’s technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

For more information, visit http://www.LexariaEnergy.com/

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides to users (1) access to our news aggregation and syndication servers, (2) enhanced press release services, and (3) a full array of social communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )



BUZ INVESTORS Proposed Cannabis Legislation Lexaria Bioscience Corp (LXRP)(CSE:LXX) (the “Company”, “Lexaria”) welcomes the newly proposed Canadian legislation designed

Lexaria Bioscience Corp. (LXRP) Announces Publication Highlighting the Operations of Several Public Cannabis-Biotech Companies

NetworkNewsWire Announces Publication Highlighting the Operations of Several Public Cannabis-Biotech Companies

Lexaria Bioscience  NetworkNewsWire (“NNW”), a multifaceted financial news and publishing
Lexaria Bioscience  PRESS RELEASE NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Lexaria Bioscience Corp. ( CSE : LXX ) ( OTCQB : LXRP ), a client of NNW that develops and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids.
The publication, entitled, “Biotech Players Lead the Growth Charge in the Legal Cannabis Market,” discusses five companies that are targeting areas of unmet medical need through cannabis-based therapies.

To view the full publication, visit: https://www.networknewswire.com/biotech-players-lead-growth-charge-legal-cannabis-market/

“Food bioscience company Lexaria Bioscience Corp. ( OTCQB : LXRP ) ( CSE : LXX ), for instance, enjoys a unique position in this sub-sector. As the only publicly traded company with a cannabis-based intellectual portfolio that includes NSAIDs, nicotine and vitamins, Lexaria has multiple patents pending in over 40 countries, and it recently received its first patents in the U.S. and Australia relating to edible forms of cannabinoids (http://nnw.fm/e8LvY).



Lexaria Bioscience

“Lexaria Energy products also utilize the company’s patented infusion technology to deliver federally legal hemp oil ingredients inside nutritious and tasty formulations that are free of the bitter taste typically associated with hemp. Products in this line include the Lexaria Energy Bar, a hemp oil-infused protein bar. Other nutritious products are in development for the Lexaria Energy line, with a focus on ensuring responsible production techniques and gluten-free formulations.”

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit www.lexariabioscience.com.

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )



Lexaria Bioscience Corp. (LXRP) Commence Laboratory Work

National Research Council and Lexaria Bioscience Commence Laboratory Work

 Lexaria Bioscience Corp. (LXRP<span data-recalc-dims=(CSE:LXX) (LXX.CN) (CNSX:LXX) (the “Company” or “Lexaria”) announces the start of laboratory work under its collaborative research program with the National Research Council of Canada (“NRC”)" width="300" height="285" srcset="https://i1.wp.com/investorsbuz.com/wp-content/uploads/2017/07/87221_01_h.jpg?resize=300%2C285&ssl=1 300w, https://i1.wp.com/investorsbuz.com/wp-content/uploads/2017/07/87221_01_h.jpg?w=525&ssl=1 525w" sizes="(max-width: 300px) 100vw, 300px" />

FOREX INVESTORS  PRESS RE:EASELexaria Bioscience Corp. (LXRP(CSE:LXX) (LXX.CN) (CNSX:LXX) (the “Company” or “Lexaria”) announces the start of laboratory work under its collaborative research program with the National Research Council of Canada (“NRC”), following the completion of preparation initiatives announced on March 14, 2017.
As earlier reported, several studies will be initiated in the coming months designed to optimize Lexaria’s patented technology enabling delivery of lipophilic active agents within foods, beverages, capsules and other ingestible formats. These studies will investigate lipophilic active agent classes including cannabinoids, vitamins, NSAIDs, and nicotine.

Advanced analytical techniques including mass spectrometry and nuclear magnetic resonance testing will be used to evaluate the chemical nature of the molecular association that Lexaria’s technology is believed to form between lipophilic active agents and the flavor and delivery enabling fatty acid agents that are integral to Lexaria’s formulation methodologies. Practical applications of this work could include further broadening or strengthening of Lexaria’s intellectual property portfolio and may also provide the foundation for new commercial arrangements.



Lexaria Bioscience

“We are delighted to have commenced formulation development and characterization work together with the NRC,” stated John Docherty, president of Lexaria Bioscience. “The NRC team has extensive knowledge and experience in the field of lipid based delivery systems relating to pharmaceutical products, natural health products and functional foods. This collaboration will significantly assist Lexaria in further developing and characterizing its IP portfolio.”

Additional information will be released upon completion and interpretation of test results.

About Lexaria
Lexaria Bioscience Corp. has developed and out-licenses its disruptive technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
www.lexariabioscience.com
Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )



MOUNTAIN HIGH ACQUISITIONS CORP (MYHI) announces that together with D9 Manufacturing, Inc. it is launching a pilot project aimed

MOUNTAIN HIGH ACQUISITIONS CORP (MYHI) rolls out Pilot Program aimed at helping Licensed Cannabis Growers

Mountain High Acquisitions Corp. rolls out Pilot Program aimed at helping Licensed Cannabis Growers overcome a Key Challenge–Financing Startup Infrastructure Costs

MOUNTAIN HIGH ACQUISITIONS CORP <span data-recalc-dims=(MYHI) announces that together with D9 Manufacturing, Inc. it is launching a pilot project aimed " width="300" height="130" srcset="https://i0.wp.com/investorsbuz.com/wp-content/uploads/2017/07/logo.png?resize=300%2C130&ssl=1 300w, https://i0.wp.com/investorsbuz.com/wp-content/uploads/2017/07/logo.png?resize=768%2C333&ssl=1 768w, https://i0.wp.com/investorsbuz.com/wp-content/uploads/2017/07/logo.png?w=800&ssl=1 800w" sizes="(max-width: 300px) 100vw, 300px" />

FOREX INVESTORS  PRESS RELEASE  MOUNTAIN HIGH ACQUISITIONS CORP (MYHI) announces that together with D9 Manufacturing, Inc. it is launching a pilot project aimed at proving a turnkey infrastructure model MYHI intends to roll out in highly promising cannabis markets such as California, Washington and Arizona.  The objective is to help licensed cannabis growers overcome the key business challenge of financing steep startup infrastructure costs.
To initiate the project, MYHI has acquired two state-of-the-art intermodal containers engineered and designed specifically for growing cannabis.  The opportunity to acquire the grow containers was presented to MYHI by D9 Manufacturing, Inc., an Arizona based company that offers a wide variety of engineering, manufacturing and consulting services to the cannabis sector.  On May 30, MYHI announced the engagement of D9 to assist in the identification, acquisition and development of infrastructure opportunities in the cannabis market.

“We are very enthusiastic about pursuing this opportunity, and appreciate what D9 has brought to the table so quickly. The solutions we intend to provide to the cannabis industry solve real problems faced by licensed growers and producers.  Having a license is not a guarantee of success.  A grower needs infrastructure and equipment that maximizes the quantity and quality of their production—and all of that can be expensive,” said MYHI CEO Alan Smith.

“That’s where we come in.  By providing swift access to affordable turnkey solutions not only do we greatly reduce setup time and costs and help growers get growing, we also help them to minimize risk and optimize their business.”




MOUNTAIN HIGH ACQUISITIONS

 

As a part of this initial pilot, MYHI will lease its first two containers to D9 for use in licensed grow operations in Arizona and California.  Grow operations in the containers are expected to begin within 30 days.  Initial harvests are anticipated to occur 90 days later.

This particular pilot project will allow the company to test both the revenue model—acquiring and leasing infrastructure solutions to licensed growers—and the equipment itself.  In this case the equipment being leased out consists of intermodal containers that can be geared for cultivation or for extraction depending upon how the container is built out.

“This pilot is just the beginning,” said Ferrel Raskin, CEO of D9 Manufacturing, Inc. “We have identified further opportunities for MYHI and D9 to pursue once this revenue model has been vetted and fine-tuned. The reality is that the cannabis industry has now matured enough so that we can identify common problems and challenges and, in turn, provide easier access to meaningful solutions.  We’re excited to be working with a partner like MYHI to ensure that these solutions are backed by sound business expertise and the ability to raise the capital required.”

About Mountain High

Mountain High Acquisitions Corp. (MYHI) is a holding company focused on the acquisition and development of businesses and other assets within the cannabis sector. For additional information please contact Alan Smith at info@mountainhighac.com.Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




Canopy Growth Corp. (TSX:WEED)(OTC:TWMJF) finished this week’s trading up more than 7%.

Canopy Growth Corp. (TSX:WEED)(OTC:TWMJF) finished this week’s trading up more than 7%.

BUZ INVESTORS Canopy Growth Corp   Canadian licensed producer, Canopy Growth Corp. finished this week’s trading up more than 7%. Last Friday, the company’s subsidiary, rTrees Producers Ltd. received their license to cultivate medical marijuana. Earlier in the week, Canopy Growth released a shareholders’ update, highlighting recent developments at the company.




Canopy Growth Corp

Canada Approves Two More Licensed Producers

$SITE_ROOT.$desktop_siteRoot.$PAGES_CONTAINER.1.1.$SITE_PAGES.$c1kod_DESKTOP.1.$ppPrt7-lx4.0.0.$child.$0.1.$1.$4.$0.0.2">$SITE_ROOT.$desktop_siteRoot.$PAGES_CONTAINER.1.1.$SITE_PAGES.$c1kod_DESKTOP.1.$ppPrt7-lx4.0.0.$child.$0.1.$1.$4.$0.0.2.0">Earlier today, Health Canada announced that two more medical marijuana producers have obtained their license to cultivate under the Access to Cannabis for Medical Purposes Regulations, or ‘ACMPR’. These two new additions come just after Health Canada granted three new licenses on Monday.

$SITE_ROOT.$desktop_siteRoot.$PAGES_CONTAINER.1.1.$SITE_PAGES.$c1kod_DESKTOP.1.$ppPrt7-lx4.0.0.$child.$0.1.$1.$4.$0.0.4">$SITE_ROOT.$desktop_siteRoot.$PAGES_CONTAINER.1.1.$SITE_PAGES.$c1kod_DESKTOP.1.$ppPrt7-lx4.0.0.$child.$0.1.$1.$4.$0.0.4.0">It is becoming clear that the recent licensing changes at Health Canada have led to a drastic change for the better in regard to the efficiency of the application process. 

$SITE_ROOT.$desktop_siteRoot.$PAGES_CONTAINER.1.1.$SITE_PAGES.$c1kod_DESKTOP.1.$ppPrt7-lx4.0.0.$child.$0.1.$1.$4.$0.0.g.0.0">, Canopy Growth Corp. (TSX:WEED)(OTC:TWMJF) acquired rTrees Producers. Under the Canopy umbrella, rTrees is operating as Tweed Grasslands and will be producing product to be$SITE_ROOT.$desktop_siteRoot.$PAGES_CONTAINER.1.1.$SITE_PAGES.$c1kod_DESKTOP.1.$ppPrt7-lx4.0.0.$child.$0.1.$1.$4.$0.0.g.0.1"> sold through the Tweed Main Street online store, $SITE_ROOT.$desktop_siteRoot.$PAGES_CONTAINER.1.1.$SITE_PAGES.$c1kod_DESKTOP.1.$ppPrt7-lx4.0.0.$child.$0.1.$1.$4.$0.0.g.0.2">among another venues. rTrees Producers has a 90,000 square foot indoor facility that has access to low cost water and power. The facility is currently $SITE_ROOT.$desktop_siteRoot.$PAGES_CONTAINER.1.1.$SITE_PAGES.$c1kod_DESKTOP.1.$ppPrt7-lx4.0.0.$child.$0.1.$1.$4.$0.0.g.0.3">20% built out. 

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




CannaRoyalty Corp  Shares of the diversified cannabis investor and operator, CannaRoyalty Corp. gained more than 11% in this week’s trading. On Monday,

CannaRoyalty Corp. (CSE:CRZ)(OTC:CNNRF) gained more than 11% in this week’s trading

CannaRoyalty Corp. (CSE:CRZ)(OTC:CNNRF) gained more than 11% in this week’s trading

 CannaRoyalty Corp  Shares of the diversified cannabis investor and operator, CannaRoyalty Corp. gained more than 11% in this week’s trading. On Monday,

BUZ INVESTORS   CannaRoyalty Corp  Shares of the diversified cannabis investor and operator, CannaRoyalty Corp. gained more than 11% in this week’s trading. On Monday, CannaRoyalty announced that the company has raised $12 million CAD (~$9.05 million USD) to form a joint venture to invest in Canadian cannabis companies.




CannaRoyalty Corp

$SITE_ROOT.$desktop_siteRoot.$PAGES_CONTAINER.1.1.$SITE_PAGES.$c1kod_DESKTOP.1.$ppPrt7-lx4.0.0.$child.$0.1.$1.$4.$0.0.2">$SITE_ROOT.$desktop_siteRoot.$PAGES_CONTAINER.1.1.$SITE_PAGES.$c1kod_DESKTOP.1.$ppPrt7-lx4.0.0.$child.$0.1.$1.$4.$0.0.2.0"> CannaRoyalty Corp. (CSE:CRZ)(CSE:CRZ.CN)(CNSX:CRZ)(OTCQX:CNNRF) (“CannaRoyalty”) is pleased to announce that it has executed a binding term sheet with a Canadian institutional investor (the “Investor”) to complete a $12 million financing and form a joint venture (“JV”) to finance opportunities in the Canadian cannabis market.

$SITE_ROOT.$desktop_siteRoot.$PAGES_CONTAINER.1.1.$SITE_PAGES.$c1kod_DESKTOP.1.$ppPrt7-lx4.0.0.$child.$0.1.$1.$4.$0.0.4">$SITE_ROOT.$desktop_siteRoot.$PAGES_CONTAINER.1.1.$SITE_PAGES.$c1kod_DESKTOP.1.$ppPrt7-lx4.0.0.$child.$0.1.$1.$4.$0.0.4.0">The financing is expected to be comprised of a revolving $12 million secured credit facility with a three year term, of which $6 million will be advanced on closing. The proceeds are expected to be used for specific opportunities that CannaRoyalty is pursuing for production and/or processing assets, as well as general corporate purposes.

$SITE_ROOT.$desktop_siteRoot.$PAGES_CONTAINER.1.1.$SITE_PAGES.$c1kod_DESKTOP.1.$ppPrt7-lx4.0.0.$child.$0.1.$1.$4.$0.0.6">$SITE_ROOT.$desktop_siteRoot.$PAGES_CONTAINER.1.1.$SITE_PAGES.$c1kod_DESKTOP.1.$ppPrt7-lx4.0.0.$child.$0.1.$1.$4.$0.0.6.0">The facility will bear interest at an annual rate of 10%, payable quarterly in cash or CannaRoyalty shares. In addition, CannaRoyalty warrants have been issued to the Investor today, which will entitle the Investor to purchase 1.8 million CannaRoyalty shares at an exercise price of $2.05 per share for a period of three years after closing.

$SITE_ROOT.$desktop_siteRoot.$PAGES_CONTAINER.1.1.$SITE_PAGES.$c1kod_DESKTOP.1.$ppPrt7-lx4.0.0.$child.$0.1.$1.$4.$0.0.8">$SITE_ROOT.$desktop_siteRoot.$PAGES_CONTAINER.1.1.$SITE_PAGES.$c1kod_DESKTOP.1.$ppPrt7-lx4.0.0.$child.$0.1.$1.$4.$0.0.8.0">The JV is expected to be launched following the closing of the financing and will focus on investment opportunities in the rapidly growing Canadian cannabis market. The Investor is a Canadian institutional investor who will fund and manage the JV. CannaRoyalty will leverage its relationships and investment pipeline to identify and refer attractive Canadian opportunities such as production assets, property and equipment to the JV and also assist the Investor in completing due diligence and providing strategic support to JV investments.

$SITE_ROOT.$desktop_siteRoot.$PAGES_CONTAINER.1.1.$SITE_PAGES.$c1kod_DESKTOP.1.$ppPrt7-lx4.0.0.$child.$0.1.$1.$4.$0.0.a">$SITE_ROOT.$desktop_siteRoot.$PAGES_CONTAINER.1.1.$SITE_PAGES.$c1kod_DESKTOP.1.$ppPrt7-lx4.0.0.$child.$0.1.$1.$4.$0.0.a.0">“Our focus on value-add assets in the cannabis sector has given us access to a broad pipeline of unique investment opportunities in Canada. This joint venture gives us a vehicle to participate in these opportunities while leveraging our joint venture partner’s expertise in hard asset lending. This JV will be the first in the cannabis sector and has the potential to provide a true “win-win-win” for target assets, the Investor and CannaRoyalty’s shareholders. Target Canadian assets get access to strategic capital; the Investor gets exposure to returns from highly productive assets in the cannabis sector; and CannaRoyalty attains exposure to accretive investment opportunities,” said Marc Lustig, CEO of CannaRoyalty.

$SITE_ROOT.$desktop_siteRoot.$PAGES_CONTAINER.1.1.$SITE_PAGES.$c1kod_DESKTOP.1.$ppPrt7-lx4.0.0.$child.$0.1.$1.$4.$0.0.c">$SITE_ROOT.$desktop_siteRoot.$PAGES_CONTAINER.1.1.$SITE_PAGES.$c1kod_DESKTOP.1.$ppPrt7-lx4.0.0.$child.$0.1.$1.$4.$0.0.c.0">In connection with the foregoing, the Investor has been granted the right to nominate a director for CannaRoyalty’s Board. Closing is expected to occur by July 31, 2017 and is subject to stock exchange approval, execution of definitive documents, completion of satisfactory due diligence, and other conditions.

$SITE_ROOT.$desktop_siteRoot.$PAGES_CONTAINER.1.1.$SITE_PAGES.$c1kod_DESKTOP.1.$ppPrt7-lx4.0.0.$child.$0.1.$1.$4.$0.0.e">$SITE_ROOT.$desktop_siteRoot.$PAGES_CONTAINER.1.1.$SITE_PAGES.$c1kod_DESKTOP.1.$ppPrt7-lx4.0.0.$child.$0.1.$1.$4.$0.0.e.0">About CannaRoyalty

$SITE_ROOT.$desktop_siteRoot.$PAGES_CONTAINER.1.1.$SITE_PAGES.$c1kod_DESKTOP.1.$ppPrt7-lx4.0.0.$child.$0.1.$1.$4.$0.0.g">$SITE_ROOT.$desktop_siteRoot.$PAGES_CONTAINER.1.1.$SITE_PAGES.$c1kod_DESKTOP.1.$ppPrt7-lx4.0.0.$child.$0.1.$1.$4.$0.0.g.0">CannaRoyalty is a fully integrated, active investor and operator in the legal cannabis sector. Our focus is building and supporting a diversified portfolio of growth-ready assets in high-value segments of the cannabis sector, including research, consumer brands, devices and intellectual property. Our management team combines a hands-on understanding of the cannabis industry with seasoned financial know-how, assembling a platform of holdings via royalty agreements, equity interests, secured convertible debt, licensing agreements and its own branded portfolio.

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




Terra Tech Announces (OTCQX: TRTC) ("Terra Tech") or (the "Company"), a vertically integrated cannabis-focused agriculture company, today announced that its new Blüm dispensary, located at 1085 South Virginia Street, Reno, Nevada, will open to patients on Monday, January 2nd, 2017 at 9:00 AM Pacific Time

Terra Tech Corp. TRTC Announces Changes in Board of Directors

|Chart | Calendar   | TRADE NOW | FORCAST | cryptocurrency 

Terra Tech Corp. Announces Changes in Board of Directors

 

BUZ INVESTORS  PRESS RELEASE  . TRTC Announces Changes  Terra Tech Corp. (TRTC) (“Terra Tech” or the “Company”), a vertically integrated cannabis-focused agriculture company, today announced Michael Vande Vrede, Steven Vande Vrede, and Amy Almsteier, one of the original co-founders of the Company, have resigned from Terra Tech’s Board of Directors, effective June 1, 2017.
Derek Peterson, Kenneth Vande Vrede, Michael Nahass, Kenneth Krueger and Steven Ross will remain on the Board of Directors. The Company plans to add more independent directors to the Board to enhance its independent oversight by incorporating best practices in corporate governance.

Derek Peterson, CEO of Terra Tech Corp., commented, “I would like to thank Mike, Steven and Amy for their contributions to Terra Tech. They have provided valuable guidance to Terra Tech since it was a fledgling cannabis company and helped to develop the Company into one of the most recognizable names in the industry. We collectively decided this is the right time for them to step down to support the Company’s commitment to best practices in corporate governance, which we believe is paramount to shareholder interests as the Company develops its nationwide presence and positions itself for an up-listing to a major stock exchange when the opportunity presents itself.”



TRTC Announces Changes

 

To be added to the Terra Tech email distribution list, please email TRTC@kcsa.com with TRTC in the subject line.

About Terra Tech

Terra Tech Corp. (TRTC) operates through multiple subsidiary businesses including: Blüm, IVXX Inc., Edible Garden, and MediFarm LLC. Blüm’s retail medical cannabis facilities focus on providing the highest quality medical cannabis to patients who are looking for alternative treatments for their chronic medical conditions. Blüm offers a broad selection of medical cannabis products including; flowers, concentrates and edibles through its Oakland, CA and multiple Nevada locations. IVXX, Inc. is a wholly-owned subsidiary of Terra Tech that produces medical cannabis-extracted products for regulated medical cannabis dispensaries throughout California. The Company’s wholly-owned subsidiary, Edible Garden, cultivates a premier brand of local and sustainably grown hydroponic produce, sold through major grocery stores such as ShopRite, Walmart, Winn-Dixie, Raley’s, Meijer, Kroger, and others throughout New Jersey, New York, Delaware, Maryland, Connecticut, Pennsylvania and the Midwest. Terra Tech’s MediFarm LLC subsidiaries are focused on medical cannabis cultivation and permitting businesses throughout Nevada.

For more information about Terra Tech Corp visit: http://www.terratechcorp.com/
For more information about IVXX visit: http://ivxx.com/
For more information about Blüm Nevada visit: http://letsblum.com
For more information about Blüm Oakland visit: http://blumoak.com/
Visit us on Facebook @ https://www.facebook.com/terratechcorp/timeline
Follow us on Twitter @terratechcorp
For more information about Edible Garden visit: http://www.ediblegarden.com/
Visit Edible Garden on Facebook @ https://www.facebook.com/ediblefarms?fref=ts
Visit IVXX on Facebook @ https://www.facebook.com/ivxxbrand?fref=ts

Cautionary Language Concerning Forward-Looking Statements

Statements in this press release may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in Terra Tech Corp.’s filings with the Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to Terra Tech Corp.’s (i) product demand, market and customer acceptance of its equipment and other goods, (ii) ability to obtain financing to expand its operations, (iii) ability to attract qualified sales representatives, (iv) competition, pricing and development difficulties, (v) ability to integrate GrowOp Technology Ltd. into its operations as a reporting issuer with the Securities and Exchange Commission, and (vi) general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on Terra Tech Corp.’s website does not constitute a part of this release.

Business Description
Industry: Farm & Construction Machinery » Farm & Construction Equipment NAICS: 333111 SIC: 3523
Compare: NAS:(ASV), OTCPK:(FBRKF), OTCPK:(AMMJ), OTCPK:(SRNA), OTCPK:(TAKD), NAS:(ARTW), NAS:(GENC), OTCPK:(INQD), NAS:(CMCO), NYSE:(TWI), OTCPK:(AGGZF), NYSE:(MTW), NYSE:(LNN), NYSE:(ALG), OTCPK:(LONKF), NAS:(ASTE), OTCPK:(WKRCF), NYSE:(JOY), NYSE:(TEX), OTCPK:(ZLIOY) » details
Headquarter Location: USA
Terra Tech Corp is an integrated cannabis-focused agriculture company which is engaged in cultivating and providing medical cannabis, as well as other agricultural products, such as herbs and leafy greens using classic Dutch hydroponic farming methods.

Terra Tech Corp was incorporated in Nevada on July 22, 2008, under the name Private Secretary, Inc. The Company changed its name to Terra Tech Corp. on January 27, 2012. On February 9, 2012, the Company completed a reverse-triangular merger with GrowOp Technology Ltd. It creates sustainable solutions for food production, indoor cultivation, rare and exotic plants, and agricultural research and development. The Company through its wholly-owned subsidiary is engaged in the design, marketing and sale of hydroponic equipment with proprietary technology to create sustainable solutions for the cultivation of indoor agriculture. It is also a retail seller of locally grown hydroponic produce through its wholly-owned subsidiary, Edible Garden Corp. Its operating and reportable segments are currently organized around the products that the Company offers as part of its core business which are Herbs, Produce and Floral Products and Cannabis Dispensary, Cultivation and Production. Its locally grown hydroponic produce is started from seed and is grown in environmentally controlled greenhouses. When harvested the products are sold through retailers targeted to customers seeking fresh produce locally grown using environmentally sustainable methods. Its cannabis products are currently produced in its lab in California and will be sold in California. The Company was granted eight provisional permits in Nevada and has received approval from the local authorities with respect to six of the eight permits. Its products include Environmental Controllers & Timers, Tents & Film, Ducting & Filtration, Fans, Ballasts, Bulbs, Reflectors, Nutrients, Portable and Hydroponic Trailers. Its subsidiary GrowOp Technology Ltd operates in two distinct markets such as commercial agriculture and retail agriculture. There are numerous manufacturers that are available to GrowOp Technology Ltd, and therefore, it is not limited in the number of suppliers available nor dependent on any one supplier. In the retail agriculture market, three main manufacturers and distributors currently dominate the market in which GrowOp Technology competes which includes Sunlight Supply, Hydrofarm, and BWGS. It’s another subsidiary Edible Garden’s main competitors are Shenadoah Growers and Sun Aqua Farms. To a lesser extent, Edible Garden competes with Green Giant, Del Monte, Rock Hedge Herbs, and Infinite Herbs.

 

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




BUZ INVESTORS Cannabinoid Joint Venture Lexaria Bioscience Corp (OTCQB:LXRP) (CSE:LXX) (the "Company") and Neutrisci International Inc ("Neutrisci") (TSX-V:NU, OTCQB:NRXCF, Frankfurt-1N9) have completed and signed the previously announced joint venture

Lexaria Bioscience Corp. LXRP Appoints New Acting CFO

|Chart | Calendar   | TRADE NOW | Lexaria

Lexaria Appoints New Acting CFO

 

BUZ INVESTORS LXRP PRESS RELEASE Appoints New Acting CFO  Lexaria Bioscience Corp. (LXRP) (CSE:LXX) (the “Company” or “Lexaria”) is pleased to announce that its has appointed Allan Spissinger as new acting CFO, Secretary and Treasurer.
Allan Spissinger was involved in the information technologies (IT) sector for more than 10 years working on corporate IT infrastructure and software development projects before focusing on finance and accounting. Allan joined the audit and assurance practice of PricewaterouseCoopers (PwC) obtaining his Chartered Professional Accountant (CPA) designation by working primarily in the public company space on financial reporting and Sarbanes-Oxley (SOX) compliance in sectors including resources, manufacturing and technologies.

Allan has managed private businesses for 20 years before joining Lexaria in September 2014 as its corporate controller and is intimately familiar with its operations, procedures and controls. “Working with the Lexaria management team has been an inspirational experience,” said Mr. Spissinger. “I look forward to my expanding role and continuing to build the exciting future that Lexaria’s patented technologies enable.”

Appoints New Acting CFO

Lexaria’s CEO Chris Bunka says, “Everyone at Lexaria welcomes Allan in his new role as CFO as we continue to strengthen our leadership team. I have every confidence in Allan and his abilities to help guide Lexaria through what we expect to be a period of phenomenal growth to come.”

Separately, the Company announces it has received US$1,540 for the exercise of 11,000 existing warrants prices at US$0.14. The Company has also settled debt of US$12,000 through the issuance of 35,294 shares at a deemed price of US$0.34. 200,000 stock options have been granted to Mr. Spissinger with an exercise price of US$0.37. No commissions or placement fees have been paid related to the funds received from this warrant exercise. Proceeds will be used for general corporate purposes.

The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Lexaria has 18 patents pending and patent applications filed in more than 40 countries worldwide.

About Lexaria:

Lexaria Bioscience Corp. is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company’s lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also improving taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company’s technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

Business Description

Industry: Consumer Packaged Goods » Packaged Foods    NAICS: 311999    SIC: 2099
Compare: AMEX:(ALN), OTCPK:(QRSRF), OTCPK:(MMMB), OTCPK:(IMMD), NAS:(RELV), OTCPK:(OPCO), NAS:(JVA), OTCPK:(TOFB), OTCPK(:HCRE), NAS:(RIBT), OTCPK:(FVRG), OTCPK:(FTLF,) OTCPK:(BABB), OTCPK:(LAGBF), OTCPK:(HISP), OTCPK:(FBER), OTCPK:(GLUC), OTCPK:J(ALA), OTCPK:(AMNF), NAS:(SNAK) » details
Traded in other countries: LXX.Canada,
Headquarter Location: Canada

Lexaria Bioscience Corp is a food sciences company. It has two distinct consumer product brands: ViPova and Lexaria Energy. It uses patent pending technology to infuse hemp oil ingredients within lipids in popular foods.

Lexaria Bioscience Corp was incorporated in the State of Nevada on December 9, 2004. It is a food sciences company focused on the delivery of hemp oil compounds procured from legal, agricultural hemp seed oil, through gourmet foods products based upon its proprietary infusion technologies. The Company produces and sells edible consumer products infused with cannabidiol. It owns two patents pending for the infusion of hemp oil within lipids. The Company has two product brands, ViPova and Lexaria Energy.

bb) Mstart(0)--sm Mstart(0)--md Mstart(33.3%) P(20px) W(1/1)--sm W(1/1)--md ie-7_W(45%)" data-reactid="38">
r) M(a) Maw(600px) Maw(800px)--lg Mih(650px) Mih(0)--sm" data-reactid="39">
r)" data-reactid="2">
bw) Cl(start) Mb(20px) Fz(15px) Lh(1.6) C(#26282a) Ff($ff-secondary) D(i)" data-reactid="10">

Under the terms of the LOI, Ambarii will manufacture and supply Ambarii CBD Tablets to Naturally Splendid for exclusive distribution in Japan and South Korea. In addition to the revenue generated from product sales, Ambarii will also receive a royalty on all sales

r)" data-reactid="2">
 

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )